scholarly article | Q13442814 |
P50 | author | Olivier Hermine | Q28322530 |
Patrice Dubreuil | Q30089953 | ||
P2093 | author name string | Ying Yang | |
Alain Moussy | |||
Jean-Pierre Kinet | |||
Phillip S Leventhal | |||
Sébastien Letard | |||
Katia Hanssens | |||
Fabienne Palmérini | |||
Stéphanie Guéry | |||
P2860 | cites work | Establishment of mouse cell lines which constitutively secrete large quantities of interleukin 2, 3, 4 or 5, using modified cDNA expression vectors | Q42805800 |
P433 | issue | 7 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | mast cell | Q191989 |
P304 | page(s) | 1137-1145 | |
P577 | publication date | 2008-07-01 | |
P1433 | published in | Molecular Cancer Research | Q2751014 |
P1476 | title | Gain-of-function mutations in the extracellular domain of KIT are common in canine mast cell tumors | |
P478 | volume | 6 |
Q35596167 | A point mutation in the extracellular domain of KIT promotes tumorigenesis of mast cells via ligand-independent auto-dimerization |
Q37333653 | A randomized trial investigating the efficacy and safety of water soluble micellar paclitaxel (Paccal Vet) for treatment of nonresectable grade 2 or 3 mast cell tumors in dogs |
Q38249785 | A retrospective review of treatment and response of high-risk mast cell tumours in dogs |
Q64063417 | A synonymous germline variant in a gene encoding a cell adhesion molecule is associated with cutaneous mast cell tumour development in Labrador and Golden Retrievers |
Q39686603 | Aberrant autophosphorylation of c-Kit receptor in canine mast cell tumor cell lines |
Q34674644 | Analysis of c-KIT exon 11 mutations in canine gastrointestinal stromal tumours |
Q38877571 | Application of post-genomic techniques in dog cancer research. |
Q50025491 | Assessment of Canine Mast Cell Tumor Mortality Risk Based on Clinical, Histologic, Immunohistochemical, and Molecular Features |
Q35017911 | Beyond H&E: integration of nucleic acid-based analyses into diagnostic pathology |
Q39560865 | Biological effect of tyrosine kinase inhibitors on three canine mast cell tumor cell lines with various KIT statuses |
Q38506396 | C-kit as a prognostic and therapeutic marker in canine cutaneous mast cell tumours: From laboratory to clinic. |
Q52889038 | CD25 is expressed by canine cutaneous mast cell tumors but not by cutaneous connective tissue mast cells. |
Q90211834 | Canine CD117-Specific Antibodies with Diverse Binding Properties Isolated from a Phage Display Library Using Cell-Based Biopanning |
Q38884478 | Canine cutaneous mast cell tumors: A combined clinical and pathologic approach to diagnosis, prognosis, and treatment selection |
Q54544577 | Canine intestinal mast cell tumor with c-kit exon 8 mutation responsive to imatinib therapy. |
Q97524610 | Canine mast cell tumors: diagnosis, treatment, and prognosis |
Q54626445 | Canine subcutaneous mast cell tumors: cellular proliferation and KIT expression as prognostic indices. |
Q92151739 | Companion Animals as Models for Inhibition of STAT3 and STAT5 |
Q57174064 | Comparative oncology: The paradigmatic example of canine and human mast cell neoplasms |
Q36873386 | Concordance of c-kit mutational status in matched primary and metastatic cutaneous canine mast cell tumors at baseline |
Q36615998 | Cutaneous mastocytosis with a mutation in the juxtamembrane domain of c-kit in a young laboratory beagle dog. |
Q21560915 | Depression in patients with mastocytosis: prevalence, features and effects of masitinib therapy |
Q54208733 | Detection of novel polymorphisms in the ckit gene of canine patients with lymphoma, melanoma, haemangiosarcoma, and osteosarcoma. |
Q33726782 | Development of an in vitro model of acquired resistance to toceranib phosphate (Palladia®) in canine mast cell tumor. |
Q52888331 | Differences in the proteome of high-grade versus low-grade canine cutaneous mast cell tumours. |
Q37154730 | Digital pathology and image analysis augment biospecimen annotation and biobank quality assurance harmonization |
Q28085473 | Dysregulation of tyrosine kinases and use of imatinib in small animal practice |
Q38033673 | European consensus document on mast cell tumours in dogs and cats |
Q38376182 | Expression of Phosphorylated KIT in Canine Mast Cell Tumor. |
Q39698999 | Expression of VEGFR and PDGFR-α/-β in 187 canine nasal carcinomas |
Q37696540 | Gene expression of growth factors and growth factor receptors for potential targeted therapy of canine hepatocellular carcinoma. |
Q37095268 | Generation and characterization of novel canine malignant mast cell line CL1. |
Q35847076 | Genome-Wide Association Study of Golden Retrievers Identifies Germ-Line Risk Factors Predisposing to Mast Cell Tumours |
Q40433142 | Genomic profiling of canine mast cell tumors identifies DNA copy number aberrations associated with KIT mutations and high histological grade |
Q44695820 | Heterogeneity of internal tandem duplications in the c-kit of dogs with multiple mast cell tumours |
Q64232058 | Heteroplasmic Mutations and Polymorphisms in the Gene of Mitochondrial DNA in Canine Mast Cell Tumours |
Q48120081 | IL-4 downregulates expression of the target receptor CD30 in neoplastic canine mast cells. |
Q40159924 | Identification of a secondary mutation in the KIT kinase domain correlated with imatinib-resistance in a canine mast cell tumor |
Q36078994 | Identification of the two KIT isoforms and their expression status in canine hemangiosarcomas |
Q54590837 | Imatinib elicited a favorable response in a dog with a mast cell tumor carrying a c-kit c.1523A>T mutation via suppression of constitutive KIT activation. |
Q34670665 | Imatinib mesylate treatment in a dog with gastrointestinal stromal tumors with a c-kit mutation |
Q33780403 | Imatinib responsiveness in canine mast cell tumors carrying novel mutations of c-KIT exon 11. |
Q43537487 | Imatinib-associated tumour response in a dog with a non-resectable gastrointestinal stromal tumour harbouring a c-kit exon 11 deletion mutation |
Q38798420 | KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells |
Q53084383 | Kit receptor tyrosine kinase dysregulations in feline splenic mast cell tumours. |
Q55043104 | Masitinib monotherapy in canine epitheliotropic lymphoma. |
Q51544382 | Mast Cell Tumors in a Llama (Lama Glama) |
Q54530545 | Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor. |
Q35839839 | Mutational Hotspot of TET2, IDH1, IDH2, SRSF2, SF3B1, KRAS, and NRAS from Human Systemic Mastocytosis Are Not Conserved in Canine Mast Cell Tumors |
Q39348704 | NI-1: a novel canine mastocytoma model for studying drug resistance and IgER-dependent mast cell activation. |
Q55366271 | Oncolytic Sendai Virus Therapy of Canine Mast Cell Tumors (A Pilot Study). |
Q35092066 | Overexpression of miR-9 in mast cells is associated with invasive behavior and spontaneous metastasis |
Q93010074 | Prevalence and prognostic value of c-kit and TP53 mutations in canine mast cell tumours |
Q47742852 | Prevalence of exon 11 internal tandem duplications in the C-KIT proto-oncogene in Australian canine mast cell tumours |
Q54452285 | Prognostic significance of Kit receptor tyrosine kinase dysregulations in feline cutaneous mast cell tumors. |
Q54315490 | RETRACTED: Diagnostic procedures for improving of the KIT (CD117) expressed allele burden for the liver metastases from uterus mast cell tumors: prognostic value of the metastatic pattern and tumor biology. |
Q58921202 | Rapid Evaluation of Mutant Exon-11 inc-kitin a Recurrent MCT Case Using CD117 Immunocytofluorescence, FACS-Cell Sorting, and PCR |
Q53313967 | Receptor Tyrosine Kinase Expression Profiles in Canine Cutaneous and Subcutaneous Mast Cell Tumors. |
Q54613659 | Safety of masitinib mesylate in healthy cats. |
Q54296742 | Sensitive detection of the c-KIT c.1430G>T mutation by mutant-specific polymerase chain reaction in feline mast cell tumours. |
Q35217229 | Sequencing and G-quadruplex folding of the canine proto-oncogene KIT promoter region: might dog be used as a model for human disease? |
Q55066232 | Small molecule kinase inhibitors in veterinary oncology. |
Q57027822 | Structural and copy number chromosome abnormalities in canine cutaneous mast cell tumours |
Q51769124 | Targeted knockdown of canine KIT (stem cell factor receptor) using RNA interference. |
Q36020577 | Targeting membrane proteins for antibody discovery using phage display. |
Q38255489 | The Relevance of CD117-Immunocytochemistry Staining Patterns to Mutational Exon-11 in c-kit Detected by PCR from Fine-Needle Aspirated Canine Mast Cell Tumor Cells |
Q89786520 | The secondary KIT mutation p.Ala510Val in a cutaneous mast cell tumour carrying the activating mutation p.Asn508Ile confers resistance to masitinib in dogs |
Q51011082 | The use of COLD-PCR, DHPLC and GeneScanning for the highly sensitive detection of c-KIT somatic mutations in canine mast cell tumours. |
Q43727603 | The value of molecular expression of KIT and KIT ligand analysed using real-time polymerase chain reaction and immunohistochemistry as a prognostic indicator for canine cutaneous mast cell tumours. |
Q51657471 | Transcriptional profiling of canine mast cell tumors: Searching for candidate targets and prognostic markers. |
Q34322014 | Transcriptome and proteome analysis of tyrosine kinase inhibitor treated canine mast cell tumour cells identifies potentially kit signaling-dependent genes |
Q64930574 | Validation of the prognostic value of histopathological grading or c-kit mutation in canine cutaneous mast cell tumours: a retrospective cohort study. |
Q54322229 | c-KIT messenger RNA and protein expression and mutations in canine cutaneous mast cell tumors: correlations with post-surgical prognosis. |
Q48196847 | c-Kit Mutation and Localization Status as Response Predictors in Mast Cell Tumors in Dogs Treated with Prednisone and Toceranib or Vinblastine. |
Q33677797 | c-Kit expression, angiogenesis, and grading in canine mast cell tumour: a unique model to study c-Kit driven human malignancies. |
Q44195615 | p62/Sequestosome-1: Mapping Sites of Protein-Handling Stress in Canine Cutaneous Mast Cell Tumors |
Search more.